Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of Octaplas in pediatric therapeutic plasma exchange
2020-000650-10Phase 4
- Sponsor
- Octapharma
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fresh-frozen plasma, sponsored by Octapharma. Primary endpoint: Safety and tolerability (serious adverse events, adverse drug reactions, thromboembolic events, transfusion-related events).
02
Drugs
fresh-frozen plasma
Beyond the preview
Go deeper on 2020-000650-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000650-10.